Treatment Guidelines: Neurodegenerative Disorders

Amyotrophic Lateral Sclerosis (ALS)
ALS Canada

• Canadian best practice recommendations for the management of amyotrophic lateral sclerosis (2020)  

American Academy of Neurology (AAN) 

• The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (2009, reaffirmed 2026)

European Academy of Neurology (EAN)

• European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD) (2024)

National Institute for Health and Care Excellence (NICE)

•  Motor neurone disease: assessment and management (2016, updated 2019) 

Huntington’s Disease (HD)
European Huntington’s Disease Network (EHDN)

• International guidelines for the treatment of Huntington's disease (2019)
• Clinical management of neuropsychiatric symptoms of Huntington disease (2018)

Huntington’s Disease Society of American (HDSA)

• A Physician's Guide to the Management of Huntington's Disease, 3rd edition (2011)

Multiple Sclerosis (MS)
American Academy of Neurology (AAN)

• Vaccine-preventable infections and immunization in multiple sclerosis (2019, reaffirmed 2025)
• Disease-modifying therapies for adults with multiple sclerosis (2018, reaffirmed 2024)
• Assessment and management of psychiatric disorders in individuals with multiple sclerosis (2014, reaffirmed 2025)
• Complementary and alternative medicine in multiple sclerosis (2014, reaffirmed 2026)

The Consortium of Multiple Sclerosis Centers (CMSC)

• Best practices in multiple sclerosis therapies (2022; updated 2025)

European Academy of Neurology (EAN)

• EAN guideline on palliative care of people with severe, progressive multiple sclerosis (2020)

European Committee for Treatment and Research in Multiple Sclerosis / European Academy of Neurology (EAN)

• ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis (2023)
• ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis (2018)

National Institute for Health and Care Excellence (NICE) 

• Multiple sclerosis in adults: management (2022, updated 2026)

Parkinson’s Disease (PD)
American Academy of Neurology (AAN)

• Dopaminergic therapy for motor symptoms in early Parkinson disease (2021)

European Academy of Neurology (EAN) / Movement Disorder Society (MDS)

• EAN/MDS guideline on the treatment of Parkinson's disease: I. Invasive therapies (2022)

International Parkinson and Movement Disorder Society (MDS)

• Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review (2025)

National Institute for Health and Care Excellence (NICE) 

• Parkinson’s disease in adults (2017, updated 2024)

The Neurourology Promotion Committee in The International Continence Society

• A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders (2016)

Parkinson Canada

• Canadian guideline for Parkinson disease (2019)

Reviewer 1: Bridgette Gleisner, PharmD, BCPP
Reviewer 2: Roisin Sabol, PharmD, BCPP
2026-2027 AAPP Resident and New Practitioner Committee